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Aims Resveratrol (RV), an antioxidant, inhibits angiotensin II (Ang II)-induced hypertrophy and Ang II- or epidermal growth
factor (EGF)-induced Akt phosphorylation in rat vascular smooth muscle cells (VSMCs). Both signalling pathways are
reported to utilize reactive oxygen species (ROS). The aim of this study was to show whether RV reduces the ROS
level in Ang II- or EGF-activated VSMCs and whether reduction of ROS causes the impeded signalling towards Akt in
the presence of RV.
Methods
and results
We show here that RV reduces intracellular ROS and extracellular H2O2 release from VSMCs as measured using
2′,7′-dichlorodihydroﬂuorescein-diacetate and Amplex RedTM. Since NADPH oxidases (Nox) 1 and 4 are major
ROS sources in VSMCs, we examined their need for Akt phosphorylation in response to Ang II or EGF. Experiments
using the blocking peptide gp91ds-tat veriﬁed a role for Nox1 in Ang II signalling towards Akt, but excluded a role for
Nox1 in the respective EGF signalling. A small interfering RNA-mediated knock-down of Nox4 showed that Nox4
was not required for Ang II- or EGF-induced Akt phosphorylation. Use of the ﬂavoprotein inhibitor diphenyleneio-
donium, N-acetyl-cysteine, and non-antioxidant RV derivatives revealed that the antioxidant capacity of RV is not
required for the inhibition of Akt phosphorylation, in both rat and human VSMCs.
Conclusion Thus, although RV acts as an antioxidant, the antihypertrophic response of RV in VSMCs and the signalling down-
stream of the EGF receptor towards Akt seem to be largely redox independent.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
The small polyphenol resveratrol (RV), found in various plant-derived
sources, including grapes, is considered to contribute to the beneﬁcial
effect of red wine in cardiovascular diseases.
1–3 Pharmacological
activities of RV relevant for a putative cardio- and vasoprotective
effect include the reduction of platelet aggregation, low-density lipo-
protein oxidation, prostaglandin synthesis, and tumour necrosis
factor-a-induced activation of endothelial cells, as well as the
promotion of endothelial nitric oxide (NO) synthase expression
and activity.
2,3 In addition, RV has been shown to inhibit
growth-related signalling pathways in cardiac ﬁbroblasts and to
protect against ischaemia–reperfusion injury.
2,3 Previous work of
our group has demonstrated an antihypertrophic action of RV in
angiotensin II (Ang II)-activated vascular smooth muscle cells
(VSMCs), which is mediated by a selective inhibition of Akt phos-
phorylation.
4,5 Angiotensin II is a potent vasoconstrictor, but is also
involved in inﬂammatory processes, vascular oxidative stress, cell
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dysfunction and vascular remodelling.
6,7 In the vessel wall, VSMCs
are the principal target cells of Ang II in which it promotes contraction
contraction, cell growth (hypertrophy), migration, and increased
extracellular matrix deposition via activation of the Ang II type 1 AT1
receptor.
7 In VSMCs, the cellular signalling pathways mediating hyper-
trophy are complex. Important steps are the activation of NAD(P)H
oxidase, a major source of cellular reactive oxygen species (ROS),
and the transactivation of the epidermal growth factor (EGF) receptor
(EGF-R) in a ROS- and c-Src-dependent manner.
6–9 Downstream of
the EGF-R, Akt and extracellular signal-regulated kinase (ERK) signalling
pathways are activated.
9 We have previously shown that RV does not
interfere with the transactivation of the EGF-R in Ang II-activated
VSMCs when inhibiting Akt phosphorylation. In accordance with this,
EGF-induced Akt phosphorylation was also inhibited by RV in
VSMCs.
5 Thus, RV interferes with the signalling towards Akt down-
stream of the EGF-R in Ang II- or EGF-activated VSMCs. The exact
mode of action of RV in VSMCs has remained elusive, although
some data have suggested activation of the redox-sensitive protein-
tyrosine phosphatase (PTP) Shp2 (Src homology-2-containing protein-
tyrosine phosphatase-2) as a mechanism.
5
Many activities of RV that are thought to contribute to its cardio-
and vasoprotective effect, including the activation of redox-sensitive
PTPs, such as Shp2, may be explained by its antioxidant activity.
2
ROS are involved in cell signaling, leading to cell growth and migration,
activation of MMPs, altered function of many kinases and phospha-
tases, and activation of pro-inﬂammatory transcription factors.
10 In
addition, ROS oxidize low-density lipoprotein and may inactivate
NO.
11 In VSMCs, the most important source of ROS are the
NAD(P)H oxidases Nox1 and Nox4.
12–14 Nox1 is highly expressed
in proliferating VSMCs and is activated by a variety of growth
factors, such as Ang II and platelet-derived growth factor, contributing
to their activation of p38 mitogen-activated protein kinase and
Akt.
13,15,16 The function of Nox4, the only constitutively active
NAD(P)H oxidase, is less clear.
15,16 In VSMCs, Nox4 was found
within distinct subcellular locations, such as the nucleus or the endo-
plasmic reticulum, but also at focal adhesions where the transactivated
EGF-R and phosphatidylinositol 3-kinase (PI3K) can be found after
Ang II stimulation.
15–18 While Nox1 is known to be required for
Ang II-induced EGF-R transactivation, little is known how the
EGF-activated EGF-R induces ROS production
19,20 that may lead to
PTP oxidation and signal transduction.
21
The aim of this study, therefore, was to investigate the following: (i)
whether RV reduces the ROS level in or H2O2 released from Ang II-
or EGF-activated VSMCs; (ii) whether Nox1 or Nox4 proteins, or
ROS in general, are required for the phosphorylation of Akt down-
stream of the EGF-R; and thus (iii) whether RV may act directly or




Materials were obtained from the following suppliers: antibodies against
phospho-Akt (Ser
473) and phospho-p38 were from Cell Signaling Technol-
ogy, anti-tubulin antibody was obtained from Santa Cruz Biotechnology.
Resveratrol, Ang II, diphenyleneiodonium (DPI) and N-acetyl-cysteine
(NAC) were purchased from Sigma-Aldrich. Epidermal growth factor
was obtained from Upstate. 2′,7′-Dichlorodihydroﬂuorescein-diacetate
(H2DCF-DA) and the Amplex RedTM reagent were from Molecular
Probes/Invitrogen. The blocking peptide for Nox1 (Nox2 is not expressed
in rat VSMCs;
22 and own unpublished results), gp91ds-tat, was
[H]-RKKRRQRRRCSTRIRRQL-NH2, and the control peptide used was
[H]-RKKRRQRRRAGAGAGAGA-NH2, both from CASLO Laboratory
ApS. All chemicals used for the synthesis of RV derivatives, unless otherwise
stated, were analytical grade and obtained from Sigma-Aldrich Chemie
GmbH (Schnelldorf, Germany), TCI Europe (Zwijndrecht, Belgium) and
Apollo Scientiﬁc Limited (Bredbury, UK) and used without further
puriﬁcation.
2.2 Cultivation of cells
The VSMCs were provided by Drs Kathy K. Griendling and Dan Sorescu
(Emory University School of Medicine) and were obtained by three inde-
pendent isolations from male Sprague–Dawley rat (200–250 g, 5–8
weeks old) thoracic aortas by enzymatic digestion as described pre-
viously.
8,23 Cells were grown in phenol red-free Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% calf serum, 2 mM glutamine,
100 U/mL penicillin, and 100 mg/mL streptomycin (growth medium). For
experiments, cells between passage 7 and 15 were used at 70% conﬂu-
ence. Prior to all growth factor stimulation experiments, cells were
starved for 24 h in Dulbecco’s modiﬁed Eagle’s medium containing 0.1%
calf serum supplemented with 2 mM glutamine, 100 U/mL penicillin, and
100 mg/mL streptomycin (starve medium).
2.3 SDS–PAGE and western blotting
For experiments, cells were grown in 60 mm dishes and serum starved
overnight in starve medium, then treated with Ang II (100 nM) or EGF
(100 ng/mL) for the indicated time. Resveratrol (50 mM), vehicle control
[dimethyl sulfoxide (DMSO) 0.1%], gp91ds-tat or the respective control
peptide (100 mM) were added 30 min before stimulation. The VSMCs
were pretreated with DPI (10 mM) for 1 h and NAC (10 mM) for 2 h
before stimulation. Cells were then suspended in lysis buffer (50 mM
HEPES, 50 mM NaCl, 5 mM EDTA, 10 mM sodium pyrophosphate,
50 mM NaF, 1 mM sodium orthovanadate, 1% Triton X-100, 1 mM phe-
nylmethylsulfonyl ﬂuoride and 1× complete protease inhibitor cocktail).
Western blot analysis was performed as described previously.
4 Proteins
of interest were visualized by the use of speciﬁc antibodies, an ECL
system and a CCD camera (Fuji LAS 3000). Densitometric evaluation
was performed by employing the AIDA image analyser 4.06 software
(Raytest).
2.4 Measurement of intracellular ROS
For detection of the intracellular total ROS level, cells were grown in
six-well plates and treated as indicated. Quiescent cells were washed
once with pre-warmed HEPES buffered saline solution and incubated at
378C for 30 min with 20 mMH 2DCF-DA before stimulation with EGF
(100 ng/mL) or Ang II (100 nM) for the indicated periods of time. Cells
were then immediately analysed by ﬂow cytometry (FACSCalibur, BD
Bioscience). The mean ﬂuorescence of 10 000 analysed cells (corrected
for autoﬂuorescence) was detected and used as a measurement for
total ROS.
2.5 Determination of extracellular H2O2 level
The VSMCs were grown in 24-well plates and serum starved for 24 h.
Cells were washed once with prewarmed phosphate-buffered saline,
then krebs ringer phosphate glucose buffer containing the Amplex
RedTM reagent was applied to the cells. Plates were incubated for
15 min at 378C before VSMCs were stimulated as indicated. Resoruﬁn,
the ﬂuorescent product, was measured in triplicate by a ﬂuorescence
multi-well plate reader with an excitation wavelength of 535 nm and an
emission wavelength of 590 nm (Genios Pro, Tecan, Switzerland).
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and quantitative real-time PCR
Five hours after seeding, VSMCs were transfected with small interfering
RNA (siRNA; siNox4 from ThermoFisher Scientiﬁc, 50 nM; or scrambled
siRNA control from Invitrogen) using Oligofectamine (Invitrogen) and
Opti-MEM 1 (Gibco). For Nox4, the sequences used were sense
5′-ACUGAGGUACAGCUGGAUGUU-3′, and antisense 5′-CAUCCAG
CUGUACCUCAGUUU-3′. Experiments were performed 72 h after
siRNA transfection. The knock-down efﬁciency was veriﬁed by quantitat-
ive real-time PCR (qPCR). For this, mRNA was isolated using the
pegGOLD total RNA Kit (Peqlab), and reverse transcription was per-
formed using SuperscriptTM First-Strand Synthesis System (Invitrogen)
according to the manufacturer’s protocol. PCR was carried out with a
LightCyclerTM LC480 SYBR Green I Master reagent (Roche Diagnostics)
and the LightCyclerTM LC480 (Roche Diagnostics) system.






on a Bruker Advance DPx200 (200 and 50 MHz). Mass spectra (MS) were
obtained by a Shimadzu (GC-17A; MS-QP5050A) spectrometer.
2.8 Statistical analysis
Results are expressed as means+SEM. Statistical analysis was performed
by ANOVA followed by Dunnett’s multiple comparison test or by one-
sample t-test using GraphPad PRISM, version 4.0 (GraphPad Software,
San Diego, CA, USA). Differences with P , 0.05 were considered
signiﬁcant.
3. Results
3.1 Resveratrol reduces intracellular total
ROS level and H2O2 release from VSMCs
First, we asked whether RV reduces intracellular total ROS level
and/or H2O2 released from VSMCs and thereby leads to inhibition
of Akt phosphorylation as described earlier.
4,5 Since NAD(P)H
Figure 1 Resveratrol (RV) diminishes intracellular reactive oxygen species (ROS) level and attenuates both basal and angiotensin II (Ang II)- or
epidermal growth factor (EGF)-induced extracellular H2O2. Quiescent vascular smooth muscle cells (VSMCs) were pre-incubated with
dichlorodihydroﬂuorescein-diacetate (H2DCF-DA; 20 mM, 15 min) and then incubated with 50 mM RV or vehicle control for 30 min or 10 mM diphe-
nyleneiodonium (DPI) for 1 h and ﬁnally stimulated with 100 nM Ang II for 15 min (A) or 100 ng/mL EGF for 10 min (B). ROS production (equivalent
to the amount of formed DCF) was analysed by ﬂow cytometry. The average ﬂuorescence signal obtained in the presence of Ang II or EGF was set to
100% (**P , 0.01; one-way ANOVA vs. Ang II or EGF treatment, n ¼ 3). Serum-starved VSMCs were stimulated in Amplex RedTM buffer with Ang II
(100 nM; C) or EGF (100 ng/mL; D) for 5–15 min after pre-incubation with RV (50 mM) or vehicle control for 30 min. H2O2 production was quanti-
ﬁed by ﬂuorescence measurement. Absolute values were correlated to catalase-treated cells used as a negative control. Graphs show the relative
extracellular H2O2 production expressed as a percentage of vehicle-treated control cells (open square, vehicle-treated cells; ﬁlled squares, RV-treated
cells; ***P , 0.001; t-test, n ¼ 4).
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an unspeciﬁc inhibitor of ﬂavin-containing enzymes including
NAD(P)H oxidases,
25 was used as positive control. For detection
of intracellular ROS, we loaded VSMCs with 20 mMH 2DCF-DA.
Angiotensin II (100 nM) was able to induce ROS production
twofold compared with the vehicle control. Resveratrol (50 mM)
and DPI (10 mM) pre-treatment reduced this ROS production
almost to the basal level (Figure 1A). In contrast, treatment of
cells with 100 ng/mL EGF, a concentration that readily induced
Akt phosphorylation, did not lead to a signiﬁcant activation of intra-
cellular ROS production in comparison with the vehicle control.
Resveratrol and DPI, however, were able to inhibit basal intracellu-
lar ROS level by about 50% (Figure 1B), verifying a strong ROS
reducing activity for both compounds. Activation of the EGF-R
has been reported to lead to increased extracellular H2O2 levels
in A431 cells.
19 Therefore, we also measured extracellular H2O2
level using Amplex RedTM. Both Ang II and EGF were able to
induce the extracellular release of H2O2 in a time-dependent
manner (Figure 1C and D). Whereas EGF treatment led to a con-
tinuous accumulation of H2O2, which was highest after 15 min
(20% above basal level), H2O2 production after Ang II stimulation
peaked at 10 min (15% above basal level). Resveratrol reduced
Ang II- and EGF-induced H2O2 but also basal levels far below
control values (Figure 1C and D). These ﬁndings demonstrate that
RV blocks both H2O2 detected in the extracellular environment
and intracellular total ROS produced in VSMCs.
3.2 A Nox4 knock-down does not inﬂuence
the phosphorylation of Akt in Ang II- or
EGF-activated VSMCs
To investigate whether Nox4 is important for the EGF- or Ang
II-induced signalling towards Akt in our cell system, Nox4 was
knocked down by siRNA. After 72 h, Nox4 mRNA level was analysed
by qPCR. The siRNA reduced the Nox4 mRNA level to 15% com-
pared with scrambled control, whereas the mRNA level of Nox1
was unchanged (Figure 2A and B). As expected, knock-down of
Nox4 had no impact on the phosphorylation of Akt after Ang II
(100 nM, 10 min) stimulation. Moreover, the inhibitory effect of RV
on Akt phosphorylation remained unaffected (Figure 2C). Interestingly,
the EGF-induced Akt phosphorylation and the inhibitory effect of RV
also remained unaltered in Nox4 knock-down cells (Figure 2D). Thus,
Nox4 seems not to be involved in Ang II- or EGF-mediated phos-
phorylation of Akt, and therefore Nox4-derived ROS are not a poten-
tial target of RV.
Figure 2 Ang II- and EGF-induced Akt phosphorylation and its
inhibition by RV occur independent of Nox4. Knock-down of
Nox4 was achieved by treating cells with 50 nM small interfering
RNA (siRNA) against Nox4 or 50 nM scrambled control siRNA
for 72 h. The mRNA was isolated, and expression of Nox4 and
Nox1 detected by qPCR. Graphs (A and B) show mean + SEM of
Nox4 mRNA (A) or Nox1 mRNA (B) level relating to 18S mRNA.
Data were normalized by setting scrambled control to 100%
(***P , 0.001; n ¼ 3). Serum-deprived Nox4 siRNA-treated cells
(50 nM, 72 h) were pre-treated with RV (50 mM, 30 min) or
vehicle control followed by stimulation with 100 nM Ang II for
10 min (C) or 100 ng/mL EGF for 5 min (D). Akt phosphorylation
and tubulin (tub, serving as a loading control) were detected by
western blot analysis. One representative blot out of three, which
were densitometrically analysed, is shown. The graphs represent
the mean densitometric values + SEM of three independent exper-
iments. Akt phosphorylation in response to Ang II or EGF of
scrambled control was set to 100% (*P , 0.05, **P , 0.01;
one-way ANOVA, n ¼ 3).
Figure 3 Inhibition of Nox1 blunts phosphorylation of Akt and
p38 induced by Ang II but does not alter EGF-induced Akt and
p38 phosphorylation. Quiescent VSMCs were pre-treated with
100 mM of the gp91ds-tat blocking peptide (gp91ds), 50 mMR Vo r
vehicle control for 30 min, and were then stimulated with 100 nM
Ang II for 10 min (A and B) or 100 ng/mL EGF (C and D) for
5 min. Akt (A and C) and p38 phosphorylation (B and D) as well
as tubulin (tub, as loading control) were detected by western blot
analysis. One representative blot out of three, which were densito-
metrically analysed, is shown. The graphs depict the mean densito-
metric values + SEM of three independent experiments. Signals
obtained in response to Ang II or EGF were set to 100%
(*P , 0.05, **P , 0.01; n.s., not signiﬁcant; one-way ANOVA vs.
Ang II or EGF treatment, n ¼ 3).
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phosphorylation in response to Ang II but
not EGF stimulation
In Ang II-activated VSMCs, Nox1 has been shown to be the major
ROS-producing component necessary for the transactivation of the
EGF-R, leading ﬁnally to Akt activation.
16 To the best of our knowl-
edge, however, it is unknown whether EGF utilizes Nox1 to transduce
its growth signal, although in transactivated settings prolonged Nox1
activation seems to need Rac1 activation via PI3K downstream of the
EGF-R.
16 To inhibit Nox1 we employed 100 mM of the blocking
peptide gp91ds-tat that prevents assembly of the Nox protein with
cofactors
12 or a control peptide. As expected, gp91ds-tat pre-
treatment led to an inhibition of Ang II-mediated Akt phosphorylation
(Figure 3A). In contrast to RV, gp91ds-tat also inhibited the phos-
phorylation of p38, a known redox-sensitive kinase, by more than
50% (Figure 3B). In EGF-activated VSMCs, gp91ds-tat, in contrast to
RV, had no effect on Akt phosphorylation (Figure 3C). A putative
effect of gp91ds-tat on p38 phosphorylation did not reach signiﬁcance
(Figure 3D). The unspeciﬁc control peptide used had no inﬂuence on
Akt or p38 phosphorylation in response to either stimulus (data not
shown). These data show that Nox1 is important for Ang II- but not
for EGF-mediated phosphorylation of Akt and p38. Inhibition of Nox1
is not able to mimic the effect of RV in our setting, and thus renders
Nox1-derived ROS an unlikely target of RV.
3.4 Both DPI and NAC inhibit Akt
phosphorylation upon Ang II but not
EGF stimulation
To further clarify the general dependency of EGF- and Ang II-induced
signalling towards Akt and p38 on ROS we applied the Nox/ﬂavopro-
tein inhibitor DPI (10 mM) and the precursor of glutathione, NAC
(10 mM). We found that Ang II-induced phosphorylation of Akt was
blocked by NAC as effectively as by RV, while DPI was less effective
(Figure 4A). In contrast to RV, which had no effect on the phosphoryl-
ation of p38 after Ang II stimulation, NAC and DPI were able to block
the phosphorylation to basal levels (Figure 4B). Phosphorylation of Akt
upon EGF stimulation was inhibited effectively only by RV; NAC and
DPI had no consistent inhibitory effect (Figure 4C). Resveratrol, NAC
or DPI did not inhibit p38 phosphorylation in response to EGF stimu-
lation (Figure 4D). These data indicate that Ang II, as described, utilizes
ROS for its signal transduction towards Akt and p38, but EGF does
not. Moreover, RV seems not to require its antioxidant activity to
inhibit Akt phosphorylation.
3.5 A non-antioxidant RV derivative
inhibits Ang II and EGF-mediated Akt
phosphorylation
To conﬁrm that RV, although redox-active, does not act as an antiox-
idant when inhibiting Akt phosphorylation we employed the following
two non-antioxidant derivatives of RV: trans-3,5,4′-trimethoxystilbene
(RV-3M) with all three hydroxyl groups methylated (Figure 5A) and
thus blunted redox activity,
26 and trans-3,5-dihydroxy-
4′-methoxystilbene (RV-1M), methylated at the 4′-OH group only
Figure 5 Non-antioxidant derivatives of RV, trans-3,5,4′-trimethoxystilbene (RV-3M; A), and trans-3,5-dihydroxy-4′-methoxystilbene (RV-1M; B).
Figure 4 DPI and NAC inhibit Ang II-induced phosphorylation of
Akt and p38. Serum-deprived cells were pre-treated with 50 mMR V
or vehicle control for 30 min, 10 mM DPI for 1 h or 10 mM NAC for
2 h, and then stimulated with 100 nM Ang II for 10 min (A and B), or
100 ng/mL EGF for 5 min (C and D). Lysates were subjected to
western blot analysis using antibodies against pAkt (A and C), pp38
(B and D) and tubulin (tub). Representative blots out of three are
shown. The graphs depict the mean + SEM of the densitometric ana-
lyses. Signals obtained in response to Ang II or EGF were set to 100%
(*P , 0.05, **P , 0.01; n.s., not signiﬁcant; one-way ANOVA vs. Ang
II or EGF treatment, n ¼ 3).
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redox inactive, since Queiroz et al. have recently shown that the
prime antioxidant pharmacophore of RV is 4′-hydroxystilbene,
27 a
ﬁnding that is also supported by others
26 and conﬁrmed by our syn-
thesized derivatives in vitro (see Supplementary material online, Figure
S1). To test their redox activity in the presence of cells we used
Amplex RedTM to detect extracellular H2O2 in the presence of RV
or its derivatives, RV-3M and RV-1M. As expected, neither of the
two derivatives was found to reduce extracellularly detected H2O2
signiﬁcantly after stimulation of VSMCs with Ang II (Figure 6A).
Using Akt phosphorylation as read-out, RV-3M inhibited neither
Ang II- nor EGF-induced Akt phosphorylation. Most interestingly,
however, the derivative RV-1M, despite its lack of inﬂuence on
H2O2, reduced phosphorylation of Akt in response to Ang II treat-
ment by over 50%, which was comparable to RV-mediated inhibition.
The EGF-induced phosphorylation of Akt was inhibited equally well
by RV-1M compared with RV (Figure 6B and C). These data clearly
show that RV inhibits Akt phosphorylation by a mechanism that is
not related to its antioxidant activity in both Ang II- and EGF-
stimulated VSMCs. In contrast, the 3- and 5-OH groups of RV seem
to be critically involved in mediating Akt inhibition. A consistent
picture of redox-independent inhibition of Akt phosphorylation by
RV and RV-1M was observed in human primary aortic smooth
muscle cells (see Supplementary material online, Figure S2).
4. Discussion
We show here for the ﬁrst time that although RV reduces total intra-
cellular ROS level and extracellular H2O2 release, its antioxidant
activity is not required for the inhibition of Akt phosphorylation in
Ang II- or EGF-activated VSMCs. Moreover, we show that in
VSMCs, EGF leads to an increase of extracellular H2O2 level but
not of intracellular ROS production. This H2O2 seems not to play a
major role for the signal transduction towards Akt and p38. Further-
more, we conﬁrm that the Ang II-induced signalling pathways towards
Akt and p38 require Nox1, and clearly show that Nox4 is not
required for Ang II- or EGF-induced Akt activation.
Many pharmacological effects of RV are believed to be related to its
antioxidant activity. In the ﬁeld of cardiovascular diseases, Opie &
Lecour recently summarized several of the RV effects that could be
linked to an antioxidant action, including inhibition of low-density lipo-
protein oxidation, inhibition of prostaglandin synthesis, down-
regulation of intercellular adhesion molecule-1 and nuclear factor-kB,
reduction of platelet activation and inhibition of Ang II-induced cardio-
myocyte hypertrophy, and they speculated that even more RV effects
might be redox related, although not proven yet.
2 Especially the
report showing that RV inhibits Ang II-induced cardiomyocyte hyper-
trophy by its antioxidant activity may be of interest in our context.
The authors show that RV (1–100 mM) inhibits Ang II-induced
[
3H]leucine incorporation as a measure for hypertrophy, beta-myosin
heavy chain promoter activity, intracellular ROS level and ERK phos-
phorylation (although not examining other kinases) in cardiomyocytes.
TolinktheantioxidantactivitytotheantihypertrophiceffectofRV,they
show that RVandtheantioxidantNACinhibit AngII-orH2O2-induced
[
3H]leucine incorporation in cardiomyocytes comparably.
28 In some
Figure 6 Non-antioxidant trans-3,5-dihydroxy-4′-methoxystilbene
(RV-1M) inhibits phosphorylation of Akt after Ang II and EGF stimu-
lation. (A) Starved VSMCs were stimulated in Amplex RedTM buffer
with Ang II (100 nM) for 10 min after pre-incubation with RV or RV
derivatives (RV, RV-3M, RV-1M; all 50 mM), or vehicle control for
30 min. H2O2 production was quantiﬁed by ﬂuorescence measure-
ment. The graph shows the relative extracellular H2O2 production
(**P , 0.01; one-way ANOVA vs. Ang II or EGF treatment, n ¼ 3).
(B and C). Serum-deprived cells were pre-treated with RV or RV
derivatives, RV-3M or RV-1M, for 30 min (50 mM), followed by
stimulation with 100 nM Ang II for 10 min (B), or 100 ng/mL EGF
for 5 min (C). Protein levels were detected by western blot using
antibodies against pAkt and tubulin. One representative blot out
of three per stimulation is shown. Graphs show the mean + SEM
of the densitometric signals; Ang II or EGF stimulation is set to
100% (**P , 0.01; one-way ANOVA vs. Ang II or EGF treatment,
n ¼ 3).
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our group, although we used VSMCs instead of cardiomyocytes; we
found an inhibition of Ang II-induced hypertrophy measured by
[
3H]leucine incorporation
4 and now also ROS production by RV.
NexttoaminoreffectonERKphosphorylation,wefoundastronginhi-
bition of the PI3K–Akt pathway leading more downstream to an effec-
tive inhibition of p70 S6 kinase important for cellular hypertrophy.
4
Here we show, however, that inhibition of ROS and Akt phosphoryl-
ation are two parallel events mediated by RV that could not be causally
linked in our system.
Our data also imply that the transduction of the signal induced by
EGF in VSMCs is less redox dependent than that of Ang II, at least
towards Akt and p38. Indeed, data regarding the ROS production
of the EGF-activated (not transactivated) EGF-R and their importance
for subsequent signal transduction are limited. The ﬁrst report
showing an intracellular increase in H2O2 production in response to
EGF used epithelial A431 cells and concentrations of EGF as high as
500 ng/mL for stimulation.
29 Halvey et al.,
20 also detecting an increase
of intracellular ROS after EGF stimulation in HaCaT cells, still used
200 ng/mL EGF. In agreement with our data, DeYulia et al.
19
showed in 293T cells transiently transfected with EGF-R that the
addition of EGF (50 ng/mL) results in elevated extracellular H2O2.
They even found that solely the receptor–ligand interaction using iso-
lated proteins was sufﬁcient to produce H2O2. The exact mechanism
by which ROS is produced, however, remained elusive. Regarding the
ROS source that might be used by the EGF-R to transduce the EGF
signal, Chen et al. proposed Nox4 that is localized at the endoplasmic
reticulum and is critical for the regulation of PTP1B. Using human
aortic endothelial cells (HAECs), and for transfection studies COS-7
cells, they suggest that Nox4-mediated oxidation and inactivation of
PTP1B in the endoplasmic reticulum serves as a regulatory switch
for EGF-R trafﬁcking that terminates the EGF signal.
30 Moreover,
both the activated EGF-R as well as Nox4 were shown to be localized
at focal adhesions in VSMCs.
31 Knocking down Nox4 in our system,
however, had no inﬂuence on EGF- as well as Ang II-induced Akt
phosphorylation, which excludes Nox4 as essential mediator of
signal transduction towards Akt downstream of the AT1- and
EGF-R as well as a potential target of RV.
While the impact of Nox4-derived ROS for a variety of physiologi-
cal processes, including cell growth, death, and differentiation is not
completely understood, the role of Nox1 in VSMC is much better
deﬁned.
16 Nox1-derived ROS was shown to regulate smooth
muscle cell growth (hypertrophy and hyperplasia) and migration.
The best-studied mechanism by which Nox1 is activated is that via
the AT1 receptor by Ang II, including activation of phospholipase C
and subsequently protein kinase C that phosphorylates p47phox, a
regulatory subunit of Nox1. Transactivation of the EGF-R leads to a
PI3K-dependent activation of Rac1 that is required for continued acti-
vation of Nox1 by Ang II.
16 Our data presented here again verify this
model; the blocking peptide gp91ds-tat effectively inhibited the Ang
II-induced signalling towards Akt and p38. In contrast, EGF-mediated
phosphorylation of Akt and p38 was not signiﬁcantly altered. We,
therefore, excluded a Nox1-dependent mechanism activating Akt or
p38 downstream of the EGF-R in our cells.
Several reports suggest an inﬂuence of RV on NAD(P)H oxidases in
non-phagocytic cells.
32–34 In our experimental set-up, however,
neither knock-down of Nox4 nor inhibition of Nox1 assembly
could mimic the RV effect. In addition, previous studies showed that
RV was unable to inhibit the transactivation of the EGF-R in Ang
II-activated VSMCs,
5 a process highly regulated by Nox1. Neverthe-
less, it remains conceivable that RV contributes to the inhibition of
Nox1-derived ROS production by the inhibition of PI3K-dependent
Rac1 at later time points.
The strongest argument against a redox-dependent mechanism of
the inhibition by RV of Ang II- or EGF-induced Akt activation came
from RV derivatives that were not acting as antioxidants but were
highly effective in inhibiting Akt phosphorylation (Figure 6). Most inter-
estingly, we found that the hydroxyl groups in the 3- and 5-positions
are sufﬁcient to block Ang II- or EGF-induced Akt phosphorylation.
Although not detected, we cannot completely exclude the possibility
that small or local rises in intracellular H2O2 are quenched by these
remaining two hydroxyl groups.
In summary, we could verify that Nox1 but not Nox4 is important
for the Ang II-induced activation of Akt and p38 in VSMCs. The signal-
ling triggered by EGF downstream of the EGF-R towards Akt and p38
phosphorylation seems to occur independently of Nox1, Nox4 or in
general of ROS. Most interestingly, we showed that RV, although
reducing intracellular ROS and extracellular H2O2 levels in VSMCs,
does not use an antioxidant mechanism to inhibit Akt phosphoryl-
ation in Ang II- or EGF-activated VSMCs.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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